West Pharmaceutical Services, Inc.

The three forensic screens point in the same direction. The Beneish M-Score is -2.791, below -1.78, and the label places it not in the elevated manipulation-risk zone. In plain terms, this model compares several ratios across two years, and a value in this range is not a flag; it is a screen, not proof of anything. The Altman Z″-Score is 9.34, in the safe zone at 2.60 or above, which describes low near-term financial distress risk on the model's assumptions. The Piotroski F-Score is 7 of 9 computable signals, a count of accounting-based health tests where seven passed. Operating cash flow of $754.8 million against net income of $493.7 million gives a ratio of 1.53, meaning 2025 cash generation exceeded reported profit. Balance-sheet growth is visible too: total assets reached $4.27 billion from $3.64 billion, and equity reached $3.18 billion from $2.68 billion, while long-term debt stayed near $202.8 million. Liabilities rose to $1.09 billion from $961.1 million. Readers may want to look at the tariff language: the 10-K says new tariffs could adversely affect results, while the 10-Q says management does not believe the impact will be material to 2026. The 10-K also flags petrochemical-linked cost pressure tied to the Middle East conflict, and Israel-based facilities reported no disruption in Q1 2026. The SmartDose 3.5mL sale to AbbVie produced $1.9 million of charges. Readers may also want to track whether the legal structure work continues to add tax costs in future quarters.

Catalyst.Growth in the first quarter of 2026 came mainly from Proprietary Products, whose net sales rose to $694.3 million from $563.0 million, a 23.3% reported increase and 17.5% excluding currency effects. Management attributes that to Westar®, NovaPure® and FluroTec® products and self-injection device platforms. West Vantage, renamed from Contract-Manufactured Products, grew to $150.6 million from $135.0 million, helped by self-injection devices for obesity and diabetes. Consolidated net sales were $844.9 million, up 21.0% as reported and 15.3% organic. For full-year 2025, revenue reached $3.07 billion, up 6.2% from 2024.

Hidden risk.The most material tension is customer concentration. The 10-K says the ten largest customers accounted for 47.6% of 2025 consolidated net sales, and one customer alone was 15.8%, or $485.9 million, spanning both segments. A change in that relationship would touch both segments at once. Separately, full-year 2025 net income of $493.7 million was nearly flat against $492.7 million in 2024 even as revenue rose. Management's adjusted figures exclude restructuring charges that appear in both the Q1 2025 and Q1 2026 reconciliations, and Q1 2026 GAAP net income included a one-time $12.0 million tax cost from an internal legal entity restructuring.